{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:05:45Z","timestamp":1777359945818,"version":"3.51.4"},"reference-count":55,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T00:00:00Z","timestamp":1294963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This work aimed at determining whether bisphosphonate therapy produces a sufficient condition for jaw osteonecrosis after tooth extraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Rats were allocated into 3 groups: (1) 11 rats treated with alendronate, (2) 10 rats treated with zoledronic acid, and (3) 10 control rats. The animals were subjected to tooth extractions, and at the end of bisphosphonate therapy, they were humanely killed. Histologic sections of the surgical site were processed and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The zoledronic acid group showed higher incidences of osteonecrosis, inflammatory infiltrate, and microorganisms. There was no significant difference for epithelial or connective tissue, root fragments, vital bone, and positive staining for vascular endothelial growth factor (VEGF) among the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Zoledronic acid is associated with jaw osteonecrosis, whereas alendronate did not produce a condition sufficient for osteonecrosis after tooth extraction. Neither zoledronic acid nor alendronate was associated with a reduced immunohistochemical expression of VEGF in vital bone at the tooth extraction site. \u00a9 2010 Wiley Periodicals, Inc. Head Neck, 2011<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.21422","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T11:02:43Z","timestamp":1272625363000},"page":"199-207","source":"Crossref","is-referenced-by-count":64,"title":["Association between bisphosphonates and jaw osteonecrosis: A study in Wistar rats"],"prefix":"10.1002","volume":"33","author":[{"given":"Marcia P.","family":"Maahs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan A.","family":"Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda G.","family":"Salum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.1.0325"},{"issue":"1","key":"e_1_2_7_3_2","first-page":"S23","article-title":"Bisphosphonates\u2014history and experimental basis","volume":"8","author":"Fleisch H","year":"1987","journal-title":"Bone"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1258\/0004563011901037"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06761.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000240885.64568.9e"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"e_1_2_7_9_2","first-page":"E76","article-title":"Osteonecrosis of the jaws and bisphosphonates. Report of three cases","volume":"11","author":"Pastor\u2010Zuazaga D","year":"2006","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.132"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2005.0108"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06762.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000187398.51857.3c"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890040313"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2003.09.001"},{"key":"e_1_2_7_17_2","unstructured":"Novartis Oncology Medical Affairs & Services. Dear doctor [letter].2004. Available at:http:\/\/www.fda.gov\/medwatch\/safety\/2004\/zometahcp.pdf."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1529-9430(03)00427-3"},{"key":"e_1_2_7_19_2","volume-title":"Zometa (zoledronic acid)\u2014intravenous formulation. Investigator's brochure for consultation","author":"Macerata R","year":"2002"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb17198.x"},{"key":"e_1_2_7_21_2","first-page":"100","volume-title":"Experimental and surgical technique in the rat","author":"Waynforth HB","year":"1992"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1258\/002367796780739871"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1258\/002367797780600297"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.01.026"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2006.09.022"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2006.02.022"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00658.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2006.0350"},{"issue":"1","key":"e_1_2_7_29_2","first-page":"S281","article-title":"Oral bioavailability and dose proportionality of alendronate (aminohydroxylbutylidene bisphosphonate) in postmenopausal women","volume":"6","author":"Gertz BJ","year":"1991","journal-title":"J Bone Miner Res"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0090-9556(25)08972-X","article-title":"Physiological disposition of alendronate, a potent anti\u2010osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin JH","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_31_2","first-page":"175","volume-title":"Practical manual of osteoporosis and mineral metabolism diseases","author":"Reszka AA","year":"2004"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035295"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1329"},{"key":"e_1_2_7_35_2","first-page":"3","volume-title":"Formulary for laboratory animals","author":"Morris TH","year":"1999"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000186470.28070.7b"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.3.346-a"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.01.010"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl294"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.2004.00269.x"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-40422005000200019"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm060492b"},{"key":"e_1_2_7_43_2","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone\u2010stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier P","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_7_44_2","first-page":"S101","article-title":"Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF\u2010I levels in the rat","volume":"49","author":"Kapitola J","year":"2000","journal-title":"Physiol Res"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.01.014"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr414"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.8.972"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1517-74912001000300013"},{"key":"e_1_2_7_49_2","first-page":"9","article-title":"A histological study of alveolar wound healing in rats after extraction and hydrogen peroxide gauze compression","volume":"26","author":"Zied IC","year":"2005","journal-title":"Rev Odontol Ara\u00e7atuba"},{"key":"e_1_2_7_50_2","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini D","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_51_2","first-page":"2893","article-title":"Zoledronic acid induces significant and long\u2010lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini D","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2007.12.004"},{"key":"e_1_2_7_53_2","first-page":"5339","article-title":"Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma","volume":"9","author":"Poon RT","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/359843a0"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5028"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn240"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.21422","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.21422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:28:03Z","timestamp":1740054483000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.21422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,14]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1002\/hed.21422"],"URL":"https:\/\/doi.org\/10.1002\/hed.21422","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,14]]}}}